The potential role of Alzheimer's disease (AD) pathology in contributing to cognitive impairment in α-synucleinopathies warrants in vivo detection of the pathological burden in patients with α-synucleinopathies.
Objective
Using a fully automated platform, we measured the levels of cerebrospinal fluid (CSF) AD biomarkers, namely Aβ42, P-tau181 and T-tau, as well as their derived ratios, P-tau181/Aβ42 ratio and T-tau/Aβ42 ratio, in a cohort of Parkinson's disease (PD), dementia with Lewy bodies (DLB), preclinical and prodromal AD (pAD) patients, as well as cognitively normal controls. We binarized the CSF biomarkers and determined the proportion of individuals with abnormal biomarker levels within each diagnostic group. We explored the associations between these biomarkers and cognitive performance.
Methods
This study consisted of 51 controls, 46 PD, 65 DLB, and 50 pAD patients. CSF biomarkers were measured using Roche Elecsys® immunoassays. Cognitive performance was based on Mini-Mental State Examination (MMSE).
Results
CSF P-tau181/Aβ42 and T-tau/Aβ42 ratios were increased in DLB and pAD, but not PD, compared with controls. Both DLB and pAD had higher proportions of individuals with abnormal CSF P-tau181/Aβ42 ratio (AD = 100%, DLB = 59%, PD = 37% and controls = 26%) and T-tau/Aβ42 ratio (AD = 100%, DLB = 51%, PD = 26% and controls = 18%). Within each diagnostic group, there was no association between CSF AD biomarkers and cognition.
Conclusions
CSF AD biomarkers profile is prevalent in DLB. Our findings highlight the potential utility of Elecsys® immunoassay platform for the evaluation of AD pathology in α-synucleinopathies.
Colom-CadenaMGrau-RiveraOPlanellasL, et al.Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol2017; 76: 216–224.
5.
HowlettDRWhitfieldDJohnsonM, et al.Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol2015; 25: 401–408.
6.
Colom-CadenaMGelpiECharifS, et al.Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol2013; 72: 1203–1212.
7.
KraybillMLLarsonEBTsuangDW, et al.Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology2005; 64: 2069–2073.
8.
JackCRJr., BennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
9.
DuboisBVillainNFrisoniGB, et al.Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol2021; 20: 484–496.
10.
ScottGDArnoldMRBeachTG, et al.Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium. Front Neurol2021; 12: 805135.
11.
WalkerZPossinKLBoeveBF, et al.Lewy body dementias. Lancet2015; 386: 1683–1697.
12.
FoskaATsantzaliISideriE, et al.Classical cerebrospinal fluid biomarkers in dementia with Lewy bodies. Medicina (Kaunas)2022; 58: 612.
13.
MollenhauerBParnettiLRektorovaI, et al.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. J Neurochem2016; 139: 290–317.
14.
van SteenovenIAarslandDWeintraubD, et al.Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis2016; 54: 287–295.
15.
AbdelnourCvan SteenovenILondosE, et al.Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord2016; 31: 1203–1208.
16.
MattssonNAndreassonUPerssonS, et al.CSF Biomarker variability in the Alzheimer's association quality control program. Alzheimers Dement2013; 9: 251–261.
17.
BittnerTZetterbergHTeunissenCE, et al.Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement2016; 12: 517–526.
18.
DoeckeJDWardLBurnhamSC, et al.Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther2020; 12: 36.
19.
HanssonOSeibylJStomrudE, et al.CSF Biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement2018; 14: 1470–1481.
20.
SchindlerSEGrayJDGordonBA, et al.Cerebrospinal fluid biomarkers measured by elecsys assays compared to amyloid imaging. Alzheimers Dement2018; 14: 1460–1469.
21.
CampbellMRAshrafzadeh-KianSPetersenRC, et al.P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst)2021; 13: e12190.
22.
JanelidzeSPanneeJMikulskisA, et al.Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol2017; 74: 1492–1501.
23.
FaganAMShawLMXiongC, et al.Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol2011; 68: 1137–1144.
OrtnerMGoldhardtODiehl-SchmidJ, et al.Elecsys cerebrospinal fluid assays accurately distinguish Alzheimer's disease from frontotemporal lobar degeneration. J Prev Alzheimers Dis2022; 9: 491–498.
27.
MarkakiINtetsikaTSorjonenK, et al.Euglycemia indicates favorable motor outcome in Parkinson's disease. Mov Disord2021; 36: 1430–1434.
28.
PaslawskiWKhosousiSHertzE, et al.Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease. Transl Neurodegener2023; 12: 42.
29.
Di CensoRAbdelnourCBlancF, et al.CSF Tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry2020; 91: 109–110.
30.
BoadaMTárragaLHernándezI, et al.Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. Alzheimers Dement2014; 10: 409–415.
31.
SkogsethRHortobágyiTSoennesynH, et al.Accuracy of clinical diagnosis of dementia with Lewy bodies versus neuropathology. J Alzheimers Dis2017; 59: 1139–1152.
32.
GiilLMAarslandDVik-MoAO. Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. Alzheimers Dement (Amst)2021; 13: e12152.
33.
AarslandDRongveANoreSP, et al.Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord2008; 26: 445–452.
34.
SiafarikasNKirsebomBESrivastavaDP, et al.Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Sci Rep2021; 11: 20375.
PostumaRBBergDSternM, et al.MDS Clinical diagnostic criteria for Parkinson's disease. Mov Disord2015; 30: 1591–1601.
37.
McKeithIGDicksonDWLoweJ, et al.Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005; 65: 1863–1872.
38.
Graff-RadfordNR. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology2014; 83: 1573–1575.
39.
MaoCShaLLiuC, et al.Cerebrospinal Fluid Alzheimer’s biomarkers and neurofilament light profile of idiopathic normal pressure hydrocephalus in China: a PUMCH cohort study. Neurodegener Dis2020; 20: 165–172.
40.
ChenZLiuCZhangJ, et al.Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Fluids Barriers CNS2017; 14: 13.
JackCRJr., KnopmanDSJagustWJ, et al.Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol2013; 12: 207–216.
43.
JackCRJr., AndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
44.
DonaghyPThomasAJO'BrienJT. Amyloid PET Imaging in Lewy body disorders. Am J Geriatr Psychiatry2015; 23: 23–37.
45.
SternYAlbertMBarnesCA, et al.A framework for concepts of reserve and resilience in aging. Neurobiol Aging2023; 124: 100–103.
46.
KantarciKLoweVJBoeveBF, et al.AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol2017; 81: 58–67.
47.
LeuzyAMattsson-CarlgrenNCullenNC, et al.Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. Alzheimers Dement2023; 19: 2994–3004.
48.
BiundoRWeisLBostantjopoulouS, et al.MMSE And MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm2016; 123: 431–438.
49.
AmftMOrtnerMEichenlaubU, et al.The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimers Res Ther2022; 14: 60.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
